Visual prosthesis

Last updated

A visual prosthesis, often referred to as a bionic eye, is an experimental visual device intended to restore functional vision in those with partial or total blindness. Many devices have been developed, usually modeled on the cochlear implant or bionic ear devices, a type of neural prosthesis in use since the mid-1980s. The idea of using electrical current (e.g., electrically stimulating the retina or the visual cortex) to provide sight dates back to the 18th century, discussed by Benjamin Franklin, [1] Tiberius Cavallo, [2] and Charles LeRoy. [3]

Contents

Biological considerations

The ability to give sight to a blind person via a bionic eye depends on the circumstances surrounding the loss of sight. For retinal prostheses, which are the most prevalent visual prosthetic under development (due to ease of access to the retina among other considerations), patients with vision loss due to degeneration of photoreceptors (retinitis pigmentosa, choroideremia, geographic atrophy macular degeneration) are the best candidate for treatment. Candidates for visual prosthetic implants find the procedure most successful if the optic nerve was developed prior to the onset of blindness. Persons born with blindness may lack a fully developed optical nerve, which typically develops prior to birth, [4] though neuroplasticity makes it possible for the nerve, and sight, to develop after implantation[ citation needed ].

Technological considerations

Visual prosthetics are being developed as a potentially valuable aid for individuals with visual degradation. Only three visual prosthetic devices have received marketing approval in the EU. [5] Argus II, co-developed at the University of Southern California (USC) Eye Institute [6] and manufactured by Second Sight Medical Products Inc., was the first device to have received marketing approval (CE Mark in Europe in 2011). Most other efforts remain investigational; the Retina Implant AG's Alpha IMS won a CE Mark July 2013 and is a significant improvement in resolution. It is not, however, FDA-approved in the US. [7]

Ongoing projects

Argus retinal prosthesis

Mark Humayun, who joined the faculty of the Keck School of Medicine of USC Department of Ophthalmology in 2001; [8] Eugene Dejuan, now at the University of California San Francisco; engineer Howard D. Phillips; bio-electronics engineer Wentai Liu, now at University of California Los Angeles; and Robert Greenberg, now of Second Sight, were the original inventors of the active epi-retinal prosthesis [9] and demonstrated proof of principle in acute patient investigations at Johns Hopkins University in the early 1990s. In the late 1990s the company Second Sight [10] was formed by Greenberg along with medical device entrepreneur, Alfred E. Mann, [11] : 35  Their first-generation implant had 16 electrodes and was implanted in six subjects by Humayun at University of Southern California between 2002 and 2004. [11] : 35  [12] In 2007, the company began a trial of its second-generation, 60-electrode implant, dubbed the Argus II, in the US and in Europe. [13] [14] In total 30 subjects participated in the studies spanning 10 sites in four countries. In the spring of 2011, based on the results of the clinical study which were published in 2012, [15] Argus II was approved for commercial use in Europe, and Second Sight launched the product later that same year. The Argus II was approved by the United States FDA on 14 February 2013. Three US government funding agencies (National Eye Institute, Department of Energy, and National Science Foundation) have supported the work at Second Sight, USC, UCSC, Caltech, and other research labs. [16]

Microsystem-based visual prosthesis (MIVP)

Designed by Claude Veraart at the University of Louvain in 2002, this is a spiral cuff electrode around the optic nerve at the back of the eye. It is connected to a stimulator implanted in a small depression in the skull. The stimulator receives signals from an externally worn camera, which are translated into electrical signals that stimulate the optic nerve directly. [17]

Implantable miniature telescope

Although not truly an active prosthesis, an implantable miniature telescope is one type of visual implant that has met with some success in the treatment of end-stage age-related macular degeneration. [18] [19] [20] This type of device is implanted in the eye's posterior chamber and works by increasing (by about three times) the size of the image projected onto the retina in order to overcome a centrally located scotoma or blind spot. [19] [20]

Created by VisionCare Ophthalmic Technologies in conjunction with the CentraSight Treatment Program in 2011, the telescope is about the size of a pea and is implanted behind the iris of one eye. Images are projected onto healthy areas of the central retina, outside the degenerated macula, and is enlarged to reduce the effect the blind spot has on central vision. 2.2x or 2.7x magnification strengths make it possible to see or discern the central vision object of interest while the other eye is used for peripheral vision because the eye that has the implant will have limited peripheral vision as a side effect. Unlike a telescope which would be hand-held, the implant moves with the eye which is the main advantage. Patients using the device may however still need glasses for optimal vision and for close work. Before surgery, patients should first try out a hand-held telescope to see if they would benefit from image enlargement. One of the main drawbacks is that it cannot be used for patients who have had cataract surgery as the intraocular lens would obstruct insertion of the telescope. It also requires a large incision in the cornea to insert. [21]

A Cochrane systematic review seeking to evaluate the effectiveness and safety of the implantable miniature telescope for patients with late or advanced age-related macular degeneration found only one ongoing study evaluating the OriLens intraocular telescope, with results expected in 2020. [22]

Tübingen MPDA Project Alpha IMS

A Southern German team led by the University Eye Hospital in Tübingen, was formed in 1995 by Eberhart Zrenner to develop a subretinal prosthesis. The chip is located behind the retina and utilizes microphotodiode arrays (MPDA) which collect incident light and transform it into electrical current stimulating the retinal ganglion cells. As natural photoreceptors are far more efficient than photodiodes, visible light is not powerful enough to stimulate the MPDA. Therefore, an external power supply is used to enhance the stimulation current. The German team commenced in vivo experiments in 2000, when evoked cortical potentials were measured from Yucatán micropigs and rabbits. At 14 months post implantation, the implant and retina surrounding it were examined and there were no noticeable changes to anatomical integrity. The implants were successful in producing evoked cortical potentials in half of the animals tested. The thresholds identified in this study were similar to those required in epiretinal stimulation. Later reports from this group concern the results of a clinical pilot study on 11 participants with retinitis pigmentosa. Some blind patients were able to read letters, recognize unknown objects, localize a plate, a cup and cutlery. [23] Two of the patients were found to make microsaccades similar to those of healthy control participants, and the properties of the eye movements depended on the stimuli that the patients were viewing—suggesting that eye movements might be useful measures for evaluating vision restored by implants. [24] [25] Multicenter study started in 2010, using a fully implantable device with 1500 Electrodes Alpha IMS (produced by Retina Implant AG, Reutlingen, Germany), with 10 patients included; preliminary results were presented at ARVO 2011.[ citation needed ] The first UK implantations took place in March 2012 and were led by Robert MacLaren at the University of Oxford and Tim Jackson at King's College Hospital in London. [26] [27] David Wong also implanted the Tübingen device in a patient in Hong Kong. [28]

On 19 March 2019 Retina Implant AG discontinued business activities quoting innovation-hostile climate of Europe's rigid regulatory and unsatisfactory results in patients. [29]

Harvard/MIT Retinal Implant

Joseph Rizzo and John Wyatt at the Massachusetts Eye and Ear Infirmary and MIT began researching the feasibility of a retinal prosthesis in 1989, and performed a number of proof-of-concept epiretinal stimulation trials on blind volunteers between 1998 and 2000. They have since developed a subretinal stimulator, an array of electrodes, that is placed beneath the retina in the subretinal space and receives image signals beamed from a camera mounted on a pair of glasses. The stimulator chip decodes the picture information beamed from the camera and stimulates retinal ganglion cells accordingly. Their second generation prosthesis collects data and sends it to the implant through radio frequency fields from transmitter coils that are mounted on the glasses. A secondary receiver coil is sutured around the iris. [30]

Artificial silicon retina (ASR)

The brothers Alan and Vincent Chow developed a microchip in 2002 containing 3500 photodiodes, which detect light and convert it into electrical impulses, which stimulate healthy retinal ganglion cells. The ASR requires no externally worn devices. [17]

The original Optobionics Corp. stopped operations, but Chow acquired the Optobionics name, the ASR implants and plans to reorganize a new company under the same name. [31] The ASR microchip is a 2mm in diameter silicon chip (same concept as computer chips) containing ~5,000 microscopic solar cells called "microphotodiodes" that each have their own stimulating electrode. [31]

Photovoltaic retinal prosthesis (PRIMA)

Daniel Palanker and his group at Stanford University developed a photovoltaic retinal prosthesis in 2012, [32] that includes a subretinal photodiode array and an infrared image projection system mounted on video goggles. Images captured by video camera are processed in a pocket PC and displayed on video goggles using pulsed near-infrared (IR, 880–915 nm) light. These images are projected onto the retina via natural eye optics, and photodiodes in the subretinal implant convert light into pulsed bi-phasic electric current in each pixel. [33] Electric current flowing through the tissue between the active and return electrode in each pixel stimulates the nearby inner retinal neurons, primarily the bipolar cells, which transmit excitatory responses to the retinal ganglion cells. This technology is being commercialized by Pixium Vision (PRIMA Archived 23 October 2018 at the Wayback Machine ), and is being evaluated in a clinical trial (2018). Following this proof of concept, Palanker group is focusing now on developing pixels smaller than 50μm using 3-D electrodes and utilizing the effect of retinal migration into voids in the subretinal implant.

Bionic Vision Technologies (BVT)

Bionic Vision Technologies (BVT) is a company, that has taken over the research and commercialisation rights of Bionic Vision Australia (BVA). BVA was a consortium of some of Australia's leading universities and research institutes, and funded by the Australian Research Council from 2010, it ceased operations on 31 December 2016. The members of the consortium consisted of Bionics Institute, UNSW Sydney, Data 61 CSRIO, Center for Eye Research Australia (CERA), and The University of Melbourne. There were many more partners as well. The Australian Federal Government awarded a $42 million ARC grant to Bionic Vision Australia to develop bionic vision technology. [34]

While the BVA consortium was still together, the team was led by Professor Anthony Burkitt, and they were developing two retinal prostheses. One known as The Wide-View device, that combined novel technologies with materials that had been successfully used in other clinical implants. This approach incorporated a microchip with 98 stimulating electrodes and aimed to provide increased mobility for patients to help them move safely in their environment. This implant would be placed in the suprachoroidal space. Researchers expected the first patient tests to begin with this device in 2013, it is currently unknown whether full trials were conducted, but at least one woman named Dianne Ashworth was implanted with the device, and was able to read letters and numbers using it., [35] she later went on to write a book titled "I Spy with My Bionic Eye", about her life, vision loss, and being the first person to be implanted with the BVA, Bionic Eye device.

BVA was also concurrently developing the High-Acuity device, which incorporated a number of new technologies to bring together a microchip and an implant with 1024 electrodes. The device aimed to provide functional central vision to assist with tasks such as face recognition and reading large print. This high-acuity implant would be inserted epiretinally. Patient tests were planned for this device in 2014 once preclinical testing had been completed, it is unknown whether these trials ever took place.

Patients with retinitis pigmentosa were to be the first to participate in the studies, followed by age-related macular degeneration. Each prototype consisted of a camera, attached to a pair of glasses which sent the signal to the implanted microchip, where it was converted into electrical impulses to stimulate the remaining healthy neurons in the retina. This information was then passed on to the optic nerve and the vision processing centres of the brain.

On 2 January 2019, BVT released positive results from a set of trials on four Australians using a new version of the device. Older versions of the device were only designed to be used temporarily, but the new design allowed the technology to be used constantly, and for the first time outside the lab, even to be taken home. More implants are to be administered throughout 2019. [36]

According to fact sheets dated March, 2019, on BVT's website, they expect the device to obtain market approval in 3 to 5 years. [37]

Dobelle Eye

Similar in function to the Harvard/MIT device, except the stimulator chip sits in the primary visual cortex, rather than on the retina. Many subjects have been implanted with a high success rate and limited negative effects. The project first began in 2002 and was still in the developmental phase, upon the death of Dobelle, selling the eye for profit was ruled against[ by whom? ] in favor of donating it to a publicly funded research team. [17] [38]

Intracortical visual prosthesis

The Laboratory of Neural Prosthetics at Illinois Institute of Technology (IIT), Chicago, started developing a visual prosthetic using intracortical electrode arrays in 2009. While similar in principle to the Dobelle system, the use of intracortical electrodes allow for greatly increased spatial resolution in the stimulation signals (more electrodes per unit area). In addition, a wireless telemetry system is being developed [39] to eliminate the need for transcranial wires. Arrays of activated iridium oxide film (AIROF)-coated electrodes will be implanted in the visual cortex, located on the occipital lobe of the brain. External hardware will capture images, process them, and generate instructions which will then be transmitted to implanted circuitry via a telemetry link. The circuitry will decode the instructions and stimulate the electrodes, in turn stimulating the visual cortex. The group is developing a wearable external image capture and processing system to accompany the implanted circuitry. Studies on animals and psychophysical studies on humans are being conducted [40] [41] to test the feasibility of a human volunteer implant.[ citation needed ]

Stephen Macknik and Susana Martinez-Conde at SUNY Downstate Medical Center are also developing an intracortical visual prosthetic, called OBServe. [42] [43] The planned system will use an LED array, a video camera, optogenetics, adeno-associated virus transfection, and eye tracking. [44] Components are currently being developed and tested in animals. [44]

See also

Related Research Articles

<span class="mw-page-title-main">Retinitis pigmentosa</span> Gradual retinal degeneration leading to progressive sight loss

Retinitis pigmentosa (RP) is a genetic disorder of the eyes that causes loss of vision. Symptoms include trouble seeing at night and decreasing peripheral vision. As peripheral vision worsens, people may experience "tunnel vision". Complete blindness is uncommon. Onset of symptoms is generally gradual and often begins in childhood.

<span class="mw-page-title-main">Macular degeneration</span> Medical condition associated with vision loss

Macular degeneration, also known as age-related macular degeneration, is a medical condition which may result in blurred or no vision in the center of the visual field. Early on there are often no symptoms. Over time, however, some people experience a gradual worsening of vision that may affect one or both eyes. While it does not result in complete blindness, loss of central vision can make it hard to recognize faces, drive, read, or perform other activities of daily life. Visual hallucinations may also occur.

The visual field is "that portion of space in which objects are visible at the same moment during steady fixation of the gaze in one direction"; in ophthalmology and neurology the emphasis is on the structure inside the visual field and it is then considered “the field of functional capacity obtained and recorded by means of perimetry”.

Neuroprosthetics is a discipline related to neuroscience and biomedical engineering concerned with developing neural prostheses. They are sometimes contrasted with a brain–computer interface, which connects the brain to a computer rather than a device meant to replace missing biological functionality.

The Lions Eye Institute (LEI) is an Australian medical research institute affiliated with the University of Western Australia. It was established in 1983 with support of the Lions Clubs of Western Australia and headquartered in the Perth suburb of Nedlands, Western Australia. The LEI is a not-for-profit centre of excellence that combines an ophthalmic clinic with scientific discovery developing techniques for the prevention of blindness and the reduction of pain from blinding eye conditions.

<span class="mw-page-title-main">Retinal implant</span>

A retinal implant is a visual prosthesis for restoration of sight to patients blinded by retinal degeneration. The system is meant to partially restore useful vision to those who have lost their photoreceptors due to retinal diseases such as retinitis pigmentosa (RP) or age-related macular degeneration (AMD). Retinal implants are being developed by a number of private companies and research institutions, and three types are in clinical trials: epiretinal, subretinal, and suprachoroidal. The implants introduce visual information into the retina by electrically stimulating the surviving retinal neurons. So far, elicited percepts had rather low resolution, and may be suitable for light perception and recognition of simple objects.

<span class="mw-page-title-main">Choroideremia</span> Medical condition

Choroideremia is a rare, X-linked recessive form of hereditary retinal degeneration that affects roughly 1 in 50,000 males. The disease causes a gradual loss of vision, starting with childhood night blindness, followed by peripheral vision loss and progressing to loss of central vision later in life. Progression continues throughout the individual's life, but both the rate of change and the degree of visual loss are variable among those affected, even within the same family.

Stargardt disease is the most common inherited single-gene retinal disease. In terms of the first description of the disease, it follows an autosomal recessive inheritance pattern, which has been later linked to bi-allelic ABCA4 gene variants (STGD1). However, there are Stargardt-like diseases with mimicking phenotypes that are referred to as STGD3 and STGD4, and have a autosomal dominant inheritance due to defects with ELOVL4 or PROM1 genes, respectively. It is characterized by macular degeneration that begins in childhood, adolescence or adulthood, resulting in progressive loss of vision.

<span class="mw-page-title-main">Intraocular hemorrhage</span> Medical condition

Intraocular hemorrhage is bleeding inside the eye. Bleeding can occur from any structure of the eye where there is vasculature or blood flow, including the anterior chamber, vitreous cavity, retina, choroid, suprachoroidal space, or optic disc.

Retinal gene therapy holds a promise in treating different forms of non-inherited and inherited blindness.

Neurostimulation is the purposeful modulation of the nervous system's activity using invasive or non-invasive means. Neurostimulation usually refers to the electromagnetic approaches to neuromodulation.

A hippocampus prosthesis is a type of cognitive prosthesis. Prosthetic devices replace normal function of a damaged body part; this can be simply a structural replacement or a rudimentary, functional replacement.

<span class="mw-page-title-main">Gholam A. Peyman</span> Iranian-American ophthalmologist and retina surgeon known for inventing LASIK eye surgery

Gholam A. Peyman is an Iranian American ophthalmologist, retina surgeon, and inventor. He is best known for his invention of LASIK eye surgery, a vision correction procedure designed to allow people to see clearly without glasses. He was awarded the first US patent for the procedure in 1989.

<span class="mw-page-title-main">Photovoltaic retinal prosthesis</span>

Photovoltaic retinal prosthesis is a technology for restoration of sight to patients blinded by degenerative retinal diseases, such as retinitis pigmentosa and age-related macular degeneration (AMD), when patients lose the 'image capturing' photoreceptors, but neurons in the 'image-processing' inner retinal layers are relatively well-preserved. This subretinal prosthesis is designed to restore sight by electrically stimulating the surviving inner retinal neurons, primarily the bipolar cells. Photovoltaic retinal implants are completely wireless and powered by near-infrared illumination (880 nm) projected from the augmented-reality glasses. Lack of trans-scleral cable greatly simplifies the implantation procedure compared to other retinal implants. Optical activation of the photovoltaic pixels allows scaling the implants to thousands of electrodes and retains natural coupling of the eye movements to visual perception. Studies in rats with retinal degeneration demonstrated that prosthetic vision with such subretinal implants preserves many features of natural vision, including flicker fusion at high frequencies (>20 Hz), adaptation to static images, antagonistic center-surround organization and non-linear summation of subunits in receptive fields, providing high spatial resolution.

<span class="mw-page-title-main">Argus retinal prosthesis</span>

Argus retinal prosthesis, also known as a bionic eye, is an electronic retinal implant manufactured by the American company Second Sight Medical Products. It is used as a visual prosthesis to improve the vision of people with severe cases of retinitis pigmentosa. The Argus II version of the system was approved for marketing in the European Union in March 2011, and it received approval in the US in February 2013 under a humanitarian device exemption. The Argus II system costs about US$150,000, excluding the cost of the implantation surgery and training to learn to use the device. Second Sight had its IPO in 2014 and was listed on Nasdaq.

José-Alain Sahel is a French ophthalmologist and scientist. He is currently the chair of the Department of Ophthalmology at the University of Pittsburgh School of Medicine, director of the UPMC Eye Center, and the Eye and Ear Foundation Chair of Ophthalmology. Dr. Sahel previously led the Vision Institute in Paris, a research center associated with one of the oldest eye hospitals of Europe - Quinze-Vingts National Eye Hospital in Paris, founded in 1260. He is a pioneer in the field of artificial retina and eye regenerative therapies. He is a member of the French Academy of Sciences.

Mark S. Humayun is a Pakistani-American ophthalmologist, engineer, scientist, inventor and academic – the only ophthalmologist elected a member of both U.S. National Academies of Medicine and Engineering. He is a university professor with joint appointments at the Keck School of Medicine of USC and the USC Viterbi School of Engineering.

A cortical implant is a subset of neuroprosthetics that is in direct connection with the cerebral cortex of the brain. By directly interfacing with different regions of the cortex, the cortical implant can provide stimulation to an immediate area and provide different benefits, depending on its design and placement. A typical cortical implant is an implantable microelectrode array, which is a small device through which a neural signal can be received or transmitted.

<span class="mw-page-title-main">Robert MacLaren</span> British ophthalmologist

Robert E. MacLaren FMedSci FRCOphth FRCS FACS VR is a British ophthalmologist who has led pioneering work in the treatment of blindness caused by diseases of the retina. He is Professor of Ophthalmology at the University of Oxford and Honorary Professor of Ophthalmology at the UCL Institute of Ophthalmology. He is a Consultant Ophthalmologist at the Oxford Eye Hospital. He is also an Honorary Consultant Vitreo-retinal Surgeon at the Moorfields Eye Hospital. MacLaren is an NIHR Senior Investigator, or lead researcher, for the speciality of Ophthalmology. In addition, he is a member of the research committee of Euretina: the European Society of Retina specialists, Fellow of Merton College, in Oxford and a Fellow of the Higher Education Academy.

<span class="mw-page-title-main">Peter Szurman</span> German ophthalmologist

Peter Szurman is a German ophthalmologist, scientist, and professor of ophthalmology in Sulzbach/Saar.

References

  1. ↑ Dobelle, Wm. H. (January 2000). "Artificial Vision for the Blind by Connecting a Television Camera to the Visual Cortex". ASAIO Journal. 46 (1): 3–9. doi:10.1097/00002480-200001000-00002. PMID   10667705.
  2. ↑ Fodstad, H.; Hariz, M. (2007). "Electricity in the treatment of nervous system disease". In Sakas, Damianos E.; Krames, Elliot S.; Simpson, Brian A. (eds.). Operative Neuromodulation. Springer. p. 11. ISBN   9783211330791 . Retrieved 21 July 2013.
  3. ↑ Sekirnjak C; Hottowy P; Sher A; Dabrowski W; et al. (2008). "High-resolution electrical stimulation of primate retina for epiretinal implant design". J Neurosci. 28 (17): 4446–56. doi:10.1523/jneurosci.5138-07.2008. PMC   2681084 . PMID   18434523.
  4. ↑ Provis, Jan M.; Van Driel, Diana; Billson, Frank A.; Russell, Peter (1 August 1985). "Human fetal optic nerve: Overproduction and elimination of retinal axons during development". The Journal of Comparative Neurology. 238 (1): 92–100. doi:10.1002/cne.902380108. PMID   4044906. S2CID   42902826.
  5. ↑ "IRIS®II becomes third bionic retina approved in Europe". fightingblindness . August 2016. Retrieved 5 August 2021.
  6. ↑ "USC Eye Institute ophthalmologists implant first FDA-approved Argus II retinal prosthesis in western United States". Reuters . 27 August 2014. Archived from the original on 5 January 2015. Retrieved 5 January 2015.
  7. ↑ Chuang, Alice T; Margo, Curtis E; Greenberg, Paul B (July 2014). "Retinal implants: a systematic review: Table 1". British Journal of Ophthalmology. 98 (7): 852–856. doi:10.1136/bjophthalmol-2013-303708. PMID   24403565. S2CID   25193594.
  8. ↑ "Humayun faculty page at USC Keck" . Retrieved 15 February 2015.
  9. ↑ U.S. Department of Energy Office of Science. "Overview of the Artificial Retina Project".
  10. ↑ "Second Sight official website". 2-sight.com. 21 May 2015. Retrieved 12 June 2018.
  11. 1 2 Second Sight. 14 November 2014 Second Sight Amendment No. 3 to Form S-1: Registration Statement
  12. ↑ Miriam Karmel (March 2012). "Clinical Update: Retina. Retinal Prostheses: Progress and Problems". Eyenet Magazine.
  13. ↑ Second Sight (9 January 2007). "Press Release: Ending the Journey through Darkness: Innovative Technology Offers New Hope for Treating Blindness due to Retinitis Pigmentosa" (PDF). Archived from the original (PDF) on 5 March 2023. Retrieved 15 February 2015.
  14. ↑ Jonathan Fildes (16 February 2007). "Trials for bionic eye implants". BBC.
  15. ↑ Humayun, Mark S.; Dorn, Jessy D.; da Cruz, Lyndon; Dagnelie, Gislin; Sahel, José-Alain; Stanga, Paulo E.; Cideciyan, Artur V.; Duncan, Jacque L.; Eliott, Dean; Filley, Eugene; Ho, Allen C.; Santos, Arturo; Safran, Avinoam B.; Arditi, Aries; Del Priore, Lucian V.; Greenberg, Robert J. (April 2012). "Interim Results from the International Trial of Second Sight's Visual Prosthesis". Ophthalmology. 119 (4): 779–788. doi:10.1016/j.ophtha.2011.09.028. PMC   3319859 . PMID   22244176.
  16. ↑ Sifferlin, Alexandra (19 February 2013). "FDA approves first bionic eye". CNN. TIME. Retrieved 22 February 2013.
  17. 1 2 3 James Geary (2002). The Body Electric. Phoenix.[ page needed ]
  18. ↑ Chun DW; Heier JS; Raizman MB (2005). "Visual prosthetic device for bilateral end-stage macular degeneration". Expert Rev Med Devices. 2 (6): 657–65. doi:10.1586/17434440.2.6.657. PMID   16293092. S2CID   40168891.
  19. 1 2 Lane SS; Kuppermann BD; Fine IH; Hamill MB; et al. (2004). "A prospective multicenter clinical trial to evaluate the safety and effectiveness of the implantable miniature telescope". Am J Ophthalmol. 137 (6): 993–1001. doi:10.1016/j.ajo.2004.01.030. PMID   15183782.
  20. 1 2 Lane SS; Kuppermann BD (2006). "The Implantable Miniature Telescope for macular degeneration". Current Opinion in Ophthalmology. 17 (1): 94–98. doi:10.1097/01.icu.0000193067.86627.a1. PMID   16436930. S2CID   28740344.
  21. ↑ Lipshitz, Isaac. "Implantable Telescope Technology". VisionCare Ophthalmic Technologies, Inc. Retrieved 20 March 2011.
  22. ↑ Gupta A, Lam J, Custis P, Munz S, Fong D, Koster M (2018). "Implantable miniature telescope (IMT) for vision loss due to end-stage age-related macular degeneration". Cochrane Database Syst Rev. 2018 (5): CD011140. doi:10.1002/14651858.CD011140.pub2. PMC   6022289 . PMID   29847689.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  23. ↑ Eberhart Zrenner; et al. (2010). "Subretinal electronic chips allow blind patients to read letters and combine them to words". Proceedings of the Royal Society B. 278 (1711): 1489–97. doi:10.1098/rspb.2010.1747. PMC   3081743 . PMID   21047851.
  24. ↑ Alexander, Robert; Macknik, Stephen; Martinez-Conde, Susana (2018). "Microsaccade Characteristics in Neurological and Ophthalmic Disease". Frontiers in Neurology. 9 (144): 144. doi: 10.3389/fneur.2018.00144 . PMC   5859063 . PMID   29593642.
  25. ↑ Hafed, Z; Stingl, K; Bartz-Schmidt, K; Gekeler, F; Zrenner, E (2016). "Oculomotor behavior of blind patients seeing with a subretinal visual implant". Vision Research. 118: 119–131. doi: 10.1016/j.visres.2015.04.006 . PMID   25906684.
  26. ↑ "Blind man 'excited' at retina implant". BBC News. 3 May 2012. Retrieved 23 May 2016.
  27. ↑ Fergus Walsh (3 May 2012). "Two blind British men have electronic retinas fitted". BBC News. Retrieved 23 May 2016.
  28. ↑ "HKU performed the first subretinal microchip implantation in Asia Patient regained eyesight after the surgery". HKU.hk (Press release). The University of Hong Kong. 3 May 2012. Retrieved 23 May 2016.
  29. ↑ "Retina Implant - Your Expert for retinitis pigmentosa - Retina Implant". www.retina-implant.de. Retrieved 10 February 2020.
  30. ↑ Wyatt, J.L. Jr. "The Retinal Implant Project" (PDF). Research Laboratory of Electronics (RLE) at the Massachusetts Institute of Technology (MIT). Retrieved 20 March 2011.
  31. 1 2 "ASR® Device". Optobionics. Retrieved 20 March 2011.
  32. ↑ Palanker Group. "Photovoltaic Retinal Prosthesis".
  33. ↑ K. Mathieson; J. Loudin; G. Goetz; P. Huie; L. Wang; T. Kamins; L. Galambos; R. Smith; J.S. Harris; A. Sher; D. Palanker (2012). "Photovoltaic retinal prosthesis with high pixel density". Nature Photonics. 6 (6): 391–97. Bibcode:2012NaPho...6..391M. doi:10.1038/nphoton.2012.104. PMC   3462820 . PMID   23049619.
  34. ↑ "About BVA". Bionicvision. Retrieved 9 August 2019.
  35. ↑ Dianne Ashworth 12 months on, 2013 , retrieved 9 August 2019
  36. ↑ Channel 9 BVT , retrieved 9 August 2019
  37. ↑ "Fact Sheets | Bionic Vision Technologies". bionicvis.com. Retrieved 9 August 2019.
  38. ↑ Simon Ings (2007). "Chapter 10(3): Making eyes to see". The Eye: a natural history. London: Bloomsbury. pp. 276–83.
  39. ↑ Rush, Alexander; PR Troyk (November 2012). "A Power and Data Link for a Wireless-Implanted Neural Recording System". IEEE Transactions on Biomedical Engineering. 59 (11): 3255–62. doi:10.1109/tbme.2012.2214385. PMID   22922687. S2CID   5412047.
  40. ↑ Srivastava, Nishant; PR Troyk; G Dagnelie (June 2009). "Detection, eye-hand coordination and virtual mobility performance in simulated vision for a cortical visual prosthesis device". Journal of Neural Engineering. 6 (3): 035008. Bibcode:2009JNEng...6c5008S. doi:10.1088/1741-2560/6/3/035008. PMC   3902177 . PMID   19458397.
  41. ↑ Lewis, Philip M.; Rosenfeld, Jeffrey V. (January 2016). "Electrical stimulation of the brain and the development of cortical visual prostheses: An historical perspective". Brain Research. 1630: 208–224. doi: 10.1016/j.brainres.2015.08.038 . PMID   26348986.
  42. ↑ Collins, Francis (27 August 2019). "The Amazing Brain: Making Up for Lost Vision". NIH Director's Blog. National Institutes of Health. Retrieved 10 November 2019.
  43. ↑ Hale, Conor. "Sidestepping failing retinas by linking cameras straight to the visual cortex". FierceBiotech. Retrieved 11 November 2019.
  44. 1 2 Macknik; Alexander; Caballero; Chanovas; Nielsen; Nishimura; Schaffer; Slovin; Babayoff; Barak; Tang; Ju; Yazdan-Shahmorad; Alonso; Malinskiy; Martinez Conde (2019). "Advanced Circuit and Cellular Imaging Methods in Nonhuman Primates". Journal of Neuroscience. 16 (42): 8267–8274. doi:10.1523/JNEUROSCI.1168-19.2019. PMC   6794937 . PMID   31619496.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.